- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06407193
Gastric Emptying After Sleeve Gastrectomy (EMRISS)
May 6, 2024 updated by: Rijnstate Hospital
Gastric Emptying Measured With MRI and Scintigraphy in Patients With Successful Versus Unsuccessful Weight Loss After Sleeve Gastrectomy
Sleeve gastrectomy (SG) increases gastrointestinal motility, which influences feelings of fullness and satiety.
By understanding the differences in gastric emptying (GE) between patients with sufficient weight loss (Total weight loss [TWL] > 35%) and insufficient weight loss (TWL < 25%), better insight in the aetiology of weight loss after sleeve gastrectomy may be obtained.
GE will be measured with scintigraphy and MRI.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Sleeve gastrectomy (SG) increases gastrointestinal motility, which influences feelings of fullness and satiety.
Patients' weight loss response on SG varies widely and is difficult to predict.
By understanding the differences in gastric emptying (GE) between patients with sufficient weight loss (Total weight loss [TWL] > 35%) and insufficient weight loss (TWL < 25%), better insight in the aetiology of weight loss after sleeve gastrectomy may be obtained.
GE will be measured with scintigraphy and MRI.
MRI is a non-invasive imaging method which provides more detailed images of the SG compared to the conventionally used scintigraphy scans.
Study Type
Observational
Enrollment (Estimated)
6
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Veerbeek
- Phone Number: +31 880052115
- Email: tveerbeek@rijnstate.nl
Study Locations
-
-
Gelderland
-
Arnhem, Gelderland, Netherlands, 6815AD
- Recruiting
- Rijnstate Hospital
-
Contact:
- Veerbeek
- Phone Number: +31 880052115
- Email: tveerbeek@rijnstate.nl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Women after sleeve gastrectomy with either good or poor weight loss
Description
Inclusion Criteria:
- Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with either TWL < 25% or TWL > 35%.
- Patients who had a follow-up period of 2-3 years after sleeve gastrectomy
Exclusion Criteria:
- Maximum BMI >50 kg/m2
- Patients with a disease known to affect appetite, gastric emptying or gastrointestinal motility
- Patients who are unable to stop medications that affect gastric emptying and/or motility prior to measurements. It is depending on t1/2 for how long they need to stop medication
- Patients who started menopause
- Patients with gastrointestinal problems or, gastric or intestinal diseases
- Patients with a drug or alcohol addiction
- Patients who are unable to stop smoking for 24h
- Patients who are pregnant or lactating
- Patients who have an intolerance or allergy for one of the components of the test product
- Patients who have a contra-indication to MRI scanning
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Poor weight loss group
Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with TWL < 25%
|
Gastric emptying measured with MRI and scintigraphy
|
Successful weight loss group
Women aged between 20 and 55 years who underwent sleeve gastrectomy as primary procedure with TWL > 35%
|
Gastric emptying measured with MRI and scintigraphy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastric emptying compared between patients with poor and successful weight loss
Time Frame: 2-3 years
|
Gastric emptying (T1/2 [min] and retention [%/min])
|
2-3 years
|
Gastric emptying compared between measured with MRI and scintigraphy
Time Frame: 2-3 years
|
Gastric emptying (T1/2 [min] and retention [%/min])
|
2-3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleeve characteristics compared between patients with successful and unsuccessful (poor) weight loss
Time Frame: 2-3 years
|
Volume (sleeve size [mL] and gastric acid [mL])
|
2-3 years
|
to assess the association between gastric emptying rate and gastric sleeve characteristics in each group
Time Frame: 2-3 years
|
association between outcome 1, 2 and 3
|
2-3 years
|
to compare subjective ratings of gastric fullness and wellbeing between patients with successful and unsuccessful weight loss
Time Frame: 2-3 years
|
questionnaires (VAS-scale, MAIA, HADS, EBBS, Power of food scale, and Food tolerance test)
|
2-3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2022
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
May 31, 2025
Study Registration Dates
First Submitted
April 25, 2024
First Submitted That Met QC Criteria
May 6, 2024
First Posted (Actual)
May 9, 2024
Study Record Updates
Last Update Posted (Actual)
May 9, 2024
Last Update Submitted That Met QC Criteria
May 6, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2020-1690
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Emptying
-
Columbia UniversityRecruiting
-
Medical University of ViennaCompleted
-
University of BergenThe Research Council of NorwayCompleted
-
Mayo ClinicCompletedGastric EmptyingUnited States
-
Air Force Military Medical University, ChinaCompleted
-
Coombe Women and Infants University HospitalCompleted
-
Kangbuk Samsung HospitalUnknown
-
Maastricht University Medical CenterUnilever R&DCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompleted
-
University Children's Hospital, ZurichCompleted
Clinical Trials on MRI and scintigraphy
-
Central Hospital, Nancy, FranceNot yet recruitingStricture of Pelviureteric JunctureFrance
-
Polarean, Inc.CompletedPulmonary Surgical ProceduresUnited States
-
Polarean, Inc.CompletedPulmonary Surgical ProceduresUnited States
-
University Hospital, BordeauxUniversité Victor Segalen Bordeaux 2Completed
-
Nottingham University Hospitals NHS TrustNational Institute for Health Research, United KingdomCompletedFunctional Dyspepsia | Diabetic GastroparesisUnited Kingdom
-
Rijnstate HospitalNot yet recruitingGastric Emptying | Bariatric SurgeryNetherlands
-
Centre Hospitalier Régional d'OrléansCompletedHeart Diseases | Neoplasms | Kidney Diseases | Parathyroid Diseases | Thyroid Diseases | Parkinsonian Disorders | Dementia | Pulmonary Embolism | Rheumatic DiseaseFrance
-
Universidade Federal FluminenseCompletedCardiovascular AbnormalitiesBrazil
-
PfizerTerminatedHeart Failure With Preserved Ejection Fraction | Transthyretin Amyloid CardiomyopathySpain, United States, Japan, Canada, France, Italy, Poland, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompleted